A B S T R A C T Recent studies from this laboratory have revealed that single nephron filtration rate (sngfr) decreases significantly within 1 h of the administration of large doses of complement-fixing antiglomerular basement membrane antibody ( the result of an 86% reduction in rpf and a decrease in LpA from 0.092+0.020 to 0.007+0.004 nl/s per g kw mm Hg (P < 0.001). Therefore, at lower doses sngfr fell primarily as a result of a 40% reduction in LpA and a 10% decrease in rpf; however, at the high dose massive reductions in both rpf and LPA led to the large decrease in sngfr.
A B S T R A C T Recent studies from this laboratory have revealed that single nephron filtration rate (sngfr) decreases significantly within 1 h of the administration of large doses of complement-fixing antiglomerular basement membrane antibody (AGBM Ab) in plasma-expanded Munich-Wistar rats. This reduction in sngfr was due to decreases in nephron plasma flow (rpf) and the glomerular permeability coefficient (LpA) utilizing direct evaluation of all pertinent pressures, flows, and permeabilities. With identical micropuncture techniques, we have determined (a) the respective influences of rpf and LpA upon sngfr by examining the effects of differing doses of AGBM Ab, and (b) the specific effect of complement fixation upon the reduction in sngfr. In normal rats, low dose (1.4 lug/g body wt) AGBM Ab decreased sngfr from 57.9+3.4 to 50.8+±3.9 nl/min per g kidney wt (kw) Received for publication 15 August 1977 and in revised form 10 November 1977. the result of an 86% reduction in rpf and a decrease in LpA from 0.092+0.020 to 0.007+0.004 nl/s per g kw mm Hg (P < 0.001). Therefore, at lower doses sngfr fell primarily as a result of a 40% reduction in LpA and a 10% decrease in rpf; however, at the high dose massive reductions in both rpf and LPA led to the large decrease in sngfr.
In complement-depleted rats, receiving identical doses, low-dose AGBM Ab no longer reduced the sngfr, but a reduction in LpA persisted (other factors compensating to maintain sngfr). At the high dose, complement depletion ameliorated the reduction in sngfr (55.1+2.4 to 37.2+3. 4 nl/min per g kw mm Hg) by nearly eliminating the vasoconstriction but only partially diminished the reduction in LpA (0.097+0.020 to 0.032+0.004 nl/s per g kw mm Hg, P < 0.05).
Complement depletion prevented the migration of polymorphonuclear leukocytes (present Two questions relevant to the specific mechanisms leading to reduced nephron filtration have been posed in this study. Firstly can we separate the respective influences of the factors that lead to reduction in sngfr: decreased rpf and reduced LpA? Secondly, what role does activation of the complement system play in reducing the filtration rate after glomerular immune injury? We have examined these two issues by studying the changes that occur in the factors influencing glomerular filtration when (a) high and low doses of AGBM Ab are administered and (b) when complement activity is depleted with cobra venom factor (2).
METHODS
Experiment animals. The current studies were performed on Munich-Wistar rats (180-240 g body wt), bred and maintained in a colony housed at the Animal Research Facility at the Veterans Administration Hospital, San Diego, Calif.
Preparation of AGBM Ab. AGBM Ab was produced by immunizing rabbits repeatedly with 10-20 mg of rat glomerular basement membrane (GBM) in complete Freund's adjuvant. Rat GBM was prepared by a modification of the method of Krakower and Greenspon (3). The attainment of nephrotoxic levels of AGBM Ab in rabbits was recognized when intravenous injection of rabbit serum induced acute 1 Abbreviations used in this paper: AGBM, Ab, antiglomerular basement membrane antibody; AR, afferent arteriolar resistance; C, protein concentration; CVF, cobra venom factor; AP, hydrostatic pressure gradient across glomerular membrane; EFP, effective filtration pressure; EFP, mean effective filtration pressure; ER, efferent arteriolar resistance; GBM, glomerular basement membrane; kw, kidney weight; L,A, glomerular permeability coefficient; ITA, systemic oncotic pressure; irE, efferent arteriolar oncotic pressure; PG, glomerular capillary hydrostatic pressure; PMN, polymorphonuclear leukocytes; Pt, Bowman's space hydrostatic pressure; rpf, nephron plasma flow; sngfr, single nephron filtration rate; x*, normalized unit glomerular capillary length. proteinuria in rats. Rabbit serum was then collected, pooled, absorbed with rat plasma and peripheral blood cells, and the gamma globulin fraction separated and concentrated by precipitation at a final concentration of 50% saturated ammonium sulfate. The gamma globulin fractions obtained by this procedure and normal rabbit gamma globulin fractions were pair labeled with I131 and I125 radioactive iodine, and the amount of kidney-fixing antibody was quantitated using the paired label isotope technique (4, 5) . The pool of AGBM Ab utilized in this study was obtained from a different group of rabbits than that used in the previous study (1) .
Methods utilized for decomplementation. Cobra venom factor (CVF; kindly prepared by Dr. Richard J. Ulevitch of Scripps Clinic and Research Foundation, La Jolla, Calif.) (6) was injected intraperitoneally into one group of rats. Each rat received 85 U/kg body wt of CVF at 48, 44, 40, 28, and 24 h before micropuncture for a total dose of 425 U/kg body wt (7) . Blood was drawn from the tail vein approximately 16 h before micropuncture surgery, and the serum assayed for C3 levels by double immunodiffusion in gel. Rats pretreated with CVF had <5% of the C3 immunoreactant normally present in the Munich-Wistar rat. The effectiveness of complement depletion in all rats studied was also assessed by immunofluorescence of the glomeruli for C3.
In separate studies, CVF at the doses used had no quantitative effect upon the binding of AGBM Ab to renal tissue as shown by the quantitative paired label radioisotope technique (4, 5) .
Micropuncture studies evaluating glomerular ultrafiltration before and after AGBM Ab. The micropuncture protocol utilized in this study was nearly identical to that described in our previous study on glomerular immune injury (1). Surgical preparation was as previously described, and all studies were paired with iso-oncotic plasma expansion (2.5% body wt administered over 60 min) which was chosen as the control condition (1) . A separate infusion of [14C]inulin dissolved in isotonic NaCl-NaHCO3 (0.5% body wt/h) was begun at the time of plasma expansion and was delivered at approximately 40 ,uCi/h.
After equilibration of radioactive inulin, control measurements of glomerular capillary and Bowman's space hydrostatic pressure (utilizing a servo-nulling device with 1-to 2-,um tip pipettes; 1, 8) and of sngfr (n = 5) were obtained and at least three samples of efferent peritubular capillary blood from "star" vessels were obtained (8) .
After completion of the control measurements, either low or high dose (1.4 or 2.3 ,ug/g kidney wt [kw]) AGBM Ab was administered intravenously over 5 min in a volume of 400 ,ul isotonic NaCl-NaHCO3. Urine flow decreased acutely with infusion of high doses of AGBM Ab but was changed little by the lower dose. 15 min after initiation of AGBM Ab infusion, all pressure, filtration rate, and efferent protein concentration measurements were repeated and completed within 45 min. In a previous study on the mechanism of glomerular immune injury with AGBM Ab, we have determined that inulin remains a valid marker of glomerular ultrafiltration even after antibody is administered (1) .
Analytic methods. Protein concentration in systemic and efferent peritubular blood samples was measured by a microadaptation of the Lowry protein method (8) (9) (10) . Sngfr, glomerular filtration rate, renal plasma flow and renal blood flow, urine and plasma sodium and potassium concentrations were determined as described in the previous study (1) .
Morphological studies. Tissue for histologic, immunofluorescent, and electron microscope studies was obtained from both kidneys at the termination of the study and processed as previously described (1, 11, 12) . The range of loops involved with 1 and 2+ changes denoting 25 and 50%, respectively. By electron microscopy, the degree of endothelial separation was graded 1 + when scattered areas or segments of separation were noted, 2+ when separation involved the entire circumference of capillary loops of some capillaries, and 3+ when roughly half of the endothelium was partially or completely separated. Foot process fusion was graded largely by the area involved with 1 and 2+ corresponding roughly to 25 and 50%, respectively. PMN approximated to the GBM were scored simply according to ease of identification, i.e., rare, occasional, or many.
Calculations. Superficial nephron filtration fraction, rpf, afferent arteriolar resistance (AR), and efferent arteriolar resistance (ER) and oncotic pressure (X) from protein concentration (C) were calculated as described in our previous publications (1, 8, 9, (13) (14) (15) .
The four factors that define the sngfr-hydrostatic pressure gradient acting across the glomerular membrane (AP), systemic oncotic pressure (ITA), glomerular permeability coefficient (LpA), and rate of rpf (6, 7) interrelate in the following manner.
Because AP = PG -Pt, where PG = directly measured glomerular capillary hydrostatic pressure and P, = Bowman's space hydrostatic pressure, the effective filtration pressure (EFP) can be defined as follows: EFP = AP -r, where ir = oncotic pressure.
As a consequence of glomerular ultrafiltration, 7T rises along the length of the glomerular capillary (x*) as a result of the increase in protein concentration (C). The mean EFP (EFP) is defined as follows:
EFP =| (AP -ir)dx*, where x* = normalized unit glomerular capillary length.
Changes in rpf modify the EFP profile along x* by affecting the rate at which protein is concentrated and the rate of rise in Xr along x*.
The sngfr can therefore be defined as follows: sngfr = LpA x EFP, where L1A is the glomerular permeability coefficient and which in turn is a product of the hydraulic conductivity (L,) of the glomerular membrane and (A) the total filtering surface area of the glomerular capillary.
Statistical analysis. The significance of data between control and experimental states among all four groups in control and experimental states was determined by two-and three-way analysis of variance and by Student's t test where appropriate (16, 17) .
RESULTS
Measurements were made both before and after AGBM Ab infusion in four separate groups-low-and highdose normal rats and low-and high-dose complementdepleted rats.
Studies utilizing either low-dose (1.4 ,g/g body wt) or high-dose (2.3 ,ug/g body wt) AGBM Ab were performed in alternating sequence with normal and complement-depleted rats. The changes in urine volume, sodium excretion, and potassium excretion after AGBM Ab infusion at both doses are summarized in Table I . All groups except the low dose of AGBM Ab in complement-depleted rats showed uniform reductions in excretion. Administration of AGBM Ab did not alter mean arterial blood pressure in any of the four respective experimental groups (P > 0.1). Effect of dose of AGBM Ab. No changes were observed on the kidney surface after low dose AGBM Ab infusion. With the higher dose, the kidney became less firm, and some decrease in color intensity of the surface was noted, possibly reflecting the reduced nephron blood flow. As shown in Table II , the mean sngfr fell somewhat (58±3 vs. 51±4 nl/min per g kw) after a low dose of AGBM Ab. This reduction was significantly greater at the higher dose 58±4 as compared to 8±4 nl/min perg kw). The mean rpf decreased minimally but significantly after the lower dose of AGBM Ab and to a significantly greater extent after the higher dose. The mean superficial nephron filtration fraction remained unchanged at both low and high doses of AGBM Ab.
Bowman's space hydrostatic pressure (P,) fell from 19±2 to 13±2 mm Hg after low-dose AGBM Ab infusion (P < 0.01; Table II ). At the higher dose Pt fell from 19±1 to 10±1 mm Hg (P < 0.001). The PG, however, was not changed by AGBM Ab at either low dose (61±3 vs. 61±2 mm Hg; P < 0.8) or high dose (60±2 vs. 55±2; P < 0.1). The net hydrostatic pressure gradient (AP) increased with both low-dose AGBM Ab (42±2 vs. 48±2 mm Hg; P < 0.02) and highdose infusion (41±1 vs. 45±2 mm Hg; P < 0.05), so that the net effect on sngfr was positive rather than negative.
The afferent (AR) and efferent (ER) arteriolar resistances were unchanged (11±1 vs. 14±3 x 109 dyn s/cm5; P > 0.3) and 10±1 vs. 12±2 x 109 dyn s/cm5; P > 0.4), respectively, after low-dose AGBM Ab infusion. However, at the higher dose AR increased from 8±1 to 161±70 x 109 dyn-s/cm5 (P < 0.001) and ER from 7.0±0.5 to 148±70 x 109 dyns/cm5 (P < 0.001).
Plasma C was identical at both the low-dose (5.8±0.2 vs. 5.8±0.1 g/100 ml) and high-dose AGBM Ab (6.3±0.2 vs. 5.9±0.3 g/100 ml; P > 0.05). The mean systemic oncotic pressure (7TA) was not altered by low and high doses ofAGBM Ab (Table II) . The hematocrits were also unchanged at either dose of AGBM Ab (P > 0.1).
The EFP at the afferent end of the glomerular capillary (EFPA) increased after administration of lowdose AGBM Ab from 23±2 to 29 ± 2 mm Hg (P < 0.01) and after high-dose infusion 19±2 vs. 25±1 mm Hg (P < 0.05). The EFP at the efferent end of the capillary (EFPE) increased from 10±3 to 17±4 mm Hg (P < 0.05) after low-dose infusion and from 9±3 to 17±2 mm Hg (P < 0.02) after the higher dose. The EFP rose from 16±3 to 23±3 mm Hg (P <0.05) after low-dose AGBM Ab administration and from 14±3 to 21±1 mm Hg (P < 0.02) after the higher dose. Finding that sngfr decreased at both doses of AGBM Ab in spite of increased EFP was also observed in our previous study on glomerular immune injury. This suggests that reductions in LpA were critical to the decrease in sngfr observed at both doses of AGBM Ab (Table II) .
The mean LpA fell after low-dose AGBM Ab infusion and decreased to a significantly greater extent (P < 0.01), as did sngfr, with the higher dose of AGBM Ab (Table II; Effect of prior complement depletion upon lowand high-dose AGBM Ab. The appearance of the kidney surface was basically unaltered in complementdepleted rats by both low and high doses of AGBM Ab which suggests that high doses of AGBM Ab have a lesser influence after complement depletion.
After complement depletion, low-dose AGBM Ab no longer significantly reduced sngfr: 50±4 vs. 47±5 nl/ min per g kw; P > 0.3; n = 9 (Table II) . At the higher dose, prior complement depletion provided an even more impressive protection effect: sngfr decreased from 55±2 to 37±3 nl/min per g kw; P < 0.005; n = 6 (Table II) , a much lesser reduction than observed in rats with an intact complement system (P < 0.005).
The beneficial effects of complement depletion were similarly observed when rpf was evaluated. The rpf was 189±17 in control and 183±21 nl/min per g kw (P > 0.5) after low-dose AGBM Ab (Table II) , signifying that complement depletion totally prevented the vasoconstriction observed in rats with intact complement given low-dose AGBM Ab. Also, with high-dose AGBM Ab, a reduction in rpf persisted, but to a much lesser extent (P < 0.005), at 209±23 and 184±30 nl/min per g kw (P < 0.01), respectively.
However, P, also decreased in the low-dose, complement-depleted group (P < 0.01; Table II ) and in the high-dose complement-depleted group. PG was unchanged by low-dose AGBM Ab infusion in the complement-depleted group as well. Similarly, highdose AGBM Ab did not alter PG. As a result, AP was now unchanged by the lower dose but increased after the high-dose Ab infusion.
AR was unchanged in the low-dose group (17±2 vs. 23±4 x 109 dyn s/cm5; P > 0.3) and at the higher dose (12+2 vs. 16±2 x 109 dyn s/cm5; P > 0.1). ER was also unchanged at the lower dose (15±3 vs. 18±5 x 109 dyn s/cm5) and higher dose (11±2 vs. 14±2 x 109 dyn s/cm5; P > 0.1).
Plasma C (CA) was reduced slightly at the lower dose (6.0±0.2 vs. 5.5±0.3 g/100 ml; P < 0.05) but was unchanged at the higher dose (6.2±0.3 vs. 6.5±0.3 g/ 100 ml; P > 0.2). Similarly, the IrA was reduced slightly in the low-dose group (Table II) but was unchanged at the higher dose.
The initial driving force for ultrafiltration was increased slightly at the lower dose (19±2 vs. 23±1 mm Hg; P < 0.05) and to a somewhat greater extent at the higher dose (19±2 vs. 25+3 mm Hg; P <0.01). The EFP at the efferent end of the capillary was 6±3 mm Hg in control and 12±2 mm Hg (P > 0.1) after lowdose infusion; it increased from 5±3 to 15±3 mm Hg (P < 0.01) after the higher dose of antibody. Although sngfr remained constant, the EFP increased at the lower dose in the complement-depleted group (12±2 vs. 18±2 mm Hg; P < 0.05). At the higher dose, the EFP, again increased from 12±2 to 20±3 mm Hg (P < 0.01).
Although sngfr remained constant, the reduction in LpA persisted with lower dose AGBM Ab infusion (0.106+0.027 vs. 0.047±0.006 nl/s per g kw mm Hg; P < 0.05) ( Table II) . The persistent decrease in LpA with no change in sngfr suggests that the beneficial effects that complement depletion exerted upon the low-dose group was mediated by preventing the vasoconstriction observed with AGBM Ab in the group with an intact complement system. The increase in EFP which permitted constant sngfr resulted from reduced ITA, decreased LpA, and a numerical increase in AP. At the higher dose, complement depletion significantly diminished the extent to which LpA was reduced (0.097±0.020 vs. 0.032±0.004 nl/s per g kw * mm Hg; P < 0.05). In fact, the L,A after highdose AGBM Ab infusion in the complement-depleted group was not different from the experimental LpA in both low-dose groups (P > 0.05) (Table II) .
In summary, complement depletion prevented the reduction in sngfr in the low-dose AGBM Ab group primarily by preventing a decrease in rpf, but did not affect the antibody-mediated reduction in LpA. At the higher dose, the decrease in sngfr persisted in spite of complement depletion, but to a much lesser degree. This beneficial effect of complement depletion at the higher dose resulted from a lesser degree of vasoconstriction and a decrease in the magnitude of reduction in LpA. However, at both doses in normal and complement-depleted rats, there remains a persistent reduction in LpA after AGBM Ab administration that appears independent of the complement system.
Immunofluorescence and morphologic findings.
Immunofluorescence study revealed that all rats had typical heavy, linear deposits of rabbit IgG along their GBM (Fig. 1) . The deposits of rabbit IgG were perhaps more prominent in the high-dose group, but the differences could not be clearly distinguished among dosage groups by immunofluorescence. Rat C3 accompanied the rabbit IgG in the normal complementemic animals (Fig. 1) . Glomerular C3 deposits were virtually absent in the complement-depleted rats (Fig. 1) .
Morphologic changes that accompanied AGBM Ab infusion were similar but quantitatively different for the four groups of rats, and there was only minor intragroup variation (Table III) . The high-dose normal complementemic group was the most severely affected. With light microscopy, PMNs could be detected easily within the glomerular capillary lumina, where as many as 15 were present per glomerulus (Fig. 2) . The endothelial cytoplasm appeared irregular which, combined with the PMNs, appeared to compromise the glomerular capillary lumina; however, the extent of compromise was dif- (Fig. 2) . The complement-depleted rats Endothelial abnormalities, approximation of PMN were virtually free of PMN accumulation in compari-along the GBM, and focal foot process fusion were son with their complementemic counterparts, and had observed in various combinations by electron microsless noticeable endothelial irregularity and little copy (Table III) . The GBM itself appeared somecompromise in their capillary lumens (Fig. 2 B and D aspect which is consistent with the fixation of AGBM Ab. Endothelial cell swelling, irregularity, and separation were most pronounced in the high-dose normal complementemic group and involved segments of the endothelium-in some glomerular capillaries the entire circumference of the endothelial lining. However, <50% of the endothelium was involved in all but two of the most severely affected rats. The endothelial changes were only slightly less pronounced in the other groups. In the normal complementemic rats, the endothelial separation often accomplished accumulation and approximation of PMNs along the denuded GBM, with PMN cytoplasm actually displacing endothelial cell cytoplasm from the underlying GBM (Fig. 3) . The number of capillary lumens containing PMNs varied in proportion to the number of PMNs identified by light microscopy; however, <20% of capillary lumens on any given section were affected, even in the most severely involved rats. When present, the PMNs rarely filled the lumen completely. The PMN approximation to the GBM was strikingly inhibited in the decomplemented animals. Rare or occasional PMNs were identified in three of the five high-dose complement-depleted rats and in three of the nine low-dose complement-depleted rats studied (Table III) . When present, the PMNs in the complement-depleted group that were attached to the GBM had roughly the same appearance as those in the normal complementemic rats.
Focal epithelial cell foot process fusion was observed in all groups (Fig. 3) . The focal areas of fusion were slightly more extensive in the high than the low-dose normal complementemic animals; somewhat fewer areas appeared in their complement-depleted counterparts (Table III) Although the qualitative conclusions that decreases in both rpf and LpA contribute to reduced filtration rate in the early phase of immune injury are common to this and our previous study on this issue (1), there were significant quantitative differences observed between the antibody preparations utilized. Doses of 225 and 450 ,ug of AGBM Ab in our previous study produced similar quantitative effects on rpf, LpA, and sngfr. However, the current microtechniques have permitted us to determine that these same low and high doses resulted in quantitative differences after the antibody utilized in this study. The specific reasons for the quantitative differences between antibody preparations generated to the same antigen is not known, but may relate to secondary effects such as the respective capacities of antibody preparations to fix complement. Also, similar high doses of antibody preparations led to different degrees of PMN accumulation, also possibly related to the complement activity generated by the respective preparations at identical doses administered.
The fixation of complement is critical in the process of immune injury. The studies of Cochrane et al. (2) , and reviews of Muller-Eberhard (18) , and Cochrane and Janoff (19) have stressed the role of complement in the pathogenesis of experimental glomerulonephritis. Activation of the complement cascade has multiple effects, including the attraction of PMN, the enhancement of cellular adherence, and the activation and release of a variety of biologically active substances. Judgments as to the role of complement fixation have been based primarily upon evaluating the renal morphology and the proteinuria that follow immune challenge (2, 18) . No studies have evaluated the possible beneficial effects upon glomerular ultrafiltration and the respective determinants of filtration that might result from preventing complement fixation.
The present studies in the complement-depleted rat and ultrastructural analysis of all experimental groups have provided information on the mechanisms leading to vasoconstriction and reduced LpA and the specific role of the complement system in the process of immune injury. CVF, which appears to be cobra C3B (20) , interacts with factors B and D of the alternative complement pathway to form a C3 cleaving enzyme (7), thereby causing C3 depletion. Complement depletion largely prevented the acute vasoconstriction that occurred at both doses of AGBM Ab. Inasmuch as the vasoconstriction was probably functional, results from studies on complement depletion suggest that vasoconstriction was not due to acute fixation of antibody alone. It is possible that activation of the complement system causes the local release of intrarenal substances capable of mediating constriction of resistance vessels. It is also possible that certain components of the complement cascade may have vasoconstrictor activity (18) . Complement depletion also prevented migration of PMN into the glomerular capillary, but this complement-mediated event is unlikely to be the direct cause of increased vascular resistance, since the cells accumulated only within the capillary, normally a region of very low resistance in the renal vasculature (15) . Our previous study on glomerular immune injury also provided evidence that the decrease in rpf and migration of PMNs were separate effects of complement activation. With a different AGBM Ab, significant vasoconstriction occurred but fewer PMNs were noted within the capillary 1 h after the infusion of the complement-fixing AGBM Ab than was noted in the high dose group in this study (1) . Although vasoconstriction and migration of PMNs are greatly dependent upon complement fixation, the two events are presumably the unrelated effects of complement activation. Where individual rats were studied, the degree of infiltration of the capillaries with PMNs correlated strongly with the degree of rpf reduction (both presumably effects of complement fixation; Table  III The first is complement dependent and related to loss of capillary surface area (A) from PMN accumulation; the second is independent ofthe complement system and due to structural alterations upon the endothelial surface ofthe capillary membrane which leads to reductions in local capillary permeability (Lp).
In a previous study on glomerular immune injury, we have postulated that fixation of antibody globulin to the GBM may have produced separation of the endothelial cell from the underlying basement membrane by interfering with the potentially charge-dependent attachment of these structures (1) . This endothelial separation may lead to a relatively less "wellstirred" compartment in which serum proteins may become concentrated from the lack of "stirring" effect of capillary blood flow. Although we 
